[go: up one dir, main page]

MX2016008150A - Formulaciones de berberina y usos de las mismas. - Google Patents

Formulaciones de berberina y usos de las mismas.

Info

Publication number
MX2016008150A
MX2016008150A MX2016008150A MX2016008150A MX2016008150A MX 2016008150 A MX2016008150 A MX 2016008150A MX 2016008150 A MX2016008150 A MX 2016008150A MX 2016008150 A MX2016008150 A MX 2016008150A MX 2016008150 A MX2016008150 A MX 2016008150A
Authority
MX
Mexico
Prior art keywords
berberine
formulations
berberine formulations
treatment
methods
Prior art date
Application number
MX2016008150A
Other languages
English (en)
Inventor
Yu Lin Way-
Ii Wang Pao-
Mao Lin Chen-
Yuan Tseng Po-
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of MX2016008150A publication Critical patent/MX2016008150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas que comprenden berberina para el tratamiento de trastornos de la piel y métodos de utilización de las mismas.
MX2016008150A 2013-12-19 2014-12-19 Formulaciones de berberina y usos de las mismas. MX2016008150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918033P 2013-12-19 2013-12-19
PCT/US2014/071364 WO2015095640A1 (en) 2013-12-19 2014-12-19 Berberine formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2016008150A true MX2016008150A (es) 2016-09-22

Family

ID=53398900

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008150A MX2016008150A (es) 2013-12-19 2014-12-19 Formulaciones de berberina y usos de las mismas.

Country Status (12)

Country Link
US (1) US9427432B2 (es)
EP (1) EP3082425A4 (es)
JP (1) JP2017500347A (es)
KR (1) KR20160098491A (es)
CN (1) CN106163280A (es)
AU (1) AU2014364357A1 (es)
CA (1) CA2933606A1 (es)
IL (1) IL246167A0 (es)
MX (1) MX2016008150A (es)
RU (1) RU2016129193A (es)
TW (1) TW201538156A (es)
WO (1) WO2015095640A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201713334A (zh) 2015-06-24 2017-04-16 安成生物科技股份有限公司 小蘗鹼製劑之治療用途
CA2995605C (en) * 2015-08-17 2024-04-02 Delivra Inc. Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
CA3049450A1 (en) * 2017-01-19 2018-07-26 Twi Biotechnology, Inc. Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
AU2019254237B2 (en) 2018-04-16 2025-01-30 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
CN115317393B (zh) * 2022-08-30 2024-07-30 南京纽邦生物科技有限公司 用于改善哺乳动物毛囊、头皮或毛发健康的方法和组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
KR100258849B1 (ko) 1998-04-24 2000-08-01 박원배 약학적으로 유용한 프로토베르베린염 유도체 및프로토베르베린유도체와 이의 염
EP1080719A3 (en) 1999-09-03 2001-04-25 Active Organics Inc. Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids
US6440465B1 (en) 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
KR101045658B1 (ko) 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
CA2766834C (en) * 2009-06-30 2017-04-25 Derman Biomedicine Co. Ltd. Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders
CN101637470B (zh) * 2009-09-07 2011-06-15 四川省医学科学院（四川省人民医院） 一种防治痤疮的外用药物组合物及其应用
CN102178731B (zh) * 2011-05-09 2012-07-11 杨志波 一种治疗慢性湿疹的中药纳米乳膏
CN102973565A (zh) * 2012-11-22 2013-03-20 安徽新陇海药业有限公司 一种含有盐酸环丙沙星化合物的药物组合物及其制备方法

Also Published As

Publication number Publication date
US9427432B2 (en) 2016-08-30
EP3082425A1 (en) 2016-10-26
CA2933606A1 (en) 2015-06-25
WO2015095640A1 (en) 2015-06-25
JP2017500347A (ja) 2017-01-05
EP3082425A4 (en) 2017-11-08
IL246167A0 (en) 2016-07-31
CN106163280A (zh) 2016-11-23
TW201538156A (zh) 2015-10-16
KR20160098491A (ko) 2016-08-18
US20150174109A1 (en) 2015-06-25
AU2014364357A1 (en) 2016-06-16
RU2016129193A (ru) 2018-01-24

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IL267997A (en) Preparations, formulations and methods for treating eye diseases
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
EP3082431A4 (en) Bacterial compositions and methods of use thereof for treatment of immune system disorders
PH12015500525A1 (en) Formulations of enzalutamide
PH12015502161A1 (en) Therapeutic compounds and compositions
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
PH12015502788A1 (en) Antibody formulations and methods
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
IL244182A0 (en) Preparations, methods and systems for the treatment of skin disorders
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
PL2989192T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
EP2999464A4 (en) Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms
EP3003341A4 (en) Compositions and methods for treatment of retinal degenerative diseases
AU2013901658A0 (en) Compositions and methods for the treatment of tinnitus